Drug intelligence / Profile preview

hypoxanthine

Development stage
Unknown
Modality
Small Molecules
01

Overview

Hypoxanthine is a naturally occurring purine derivative and an intermediate in the metabolism of adenosine and nucleic acids via the salvage pathway. It is present in cells as a constituent of nucleic acids, particularly in tRNA as its nucleoside inosine. Hypoxanthine serves as a substrate and nitrogen source for certain cell, bacterial, and parasite cultures—most notably required for *Plasmodium falciparum* (malaria parasite) growth due to its role in nucleic acid synthesis and energy metabolism. In biological systems, it is produced from adenine by deamination or from AMP/IMP during ATP consumption (e.g., muscle contraction). Hypoxanthine can be oxidized to xanthine by xanthine oxidoreductase. It also acts as a potential free radical generator involved in posthypoxic reoxygenation injury through oxygen radical production, modulates benzodiazepine receptors, inhibits brain phosphodiesterase activity, and may influence cytotoxic drug effects[1][2][5][8].

Other names
hypoxanthine6-hydroxypurinesarkinsarcinepurin-6(1H)-onepurinone9H-purin-6(1H)-onepurinone enol form7H-purin–6–ol3H-purin–6–ol
02

Targets

HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase)XO (Xanthine Oxidoreductase)

Beyond the preview

Go deeper on hypoxanthine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hypoxanthine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call